Business Wire

GoCardless Welcomes Paul Stoddart as President

4.5.2022 02:01:00 EEST | Business Wire | Press release

Share

GoCardless, a leader in direct bank payment solutions, today announced the appointment of Paul Stoddart as President. Stoddart joins from Mastercard where he was President of its New Payment Platforms, Executive Chairman of Vocalink and a Member of the Mastercard Management Committee. In his new role at GoCardless he will have global responsibility for the go-to-market organisation including the Strategy, Sales, Product, Marketing and Customer teams, with a view to accelerating growth and achieving the company’s ambition to become the world’s bank payment network.

Stoddart brings a wealth of experience to GoCardless. He was named as Chief Executive Officer of Vocalink after its acquisition by Mastercard and subsequently promoted to President of Mastercard’s New Payment Platforms where he led the establishment and growth of a business unit that expanded Mastercard’s role in payments beyond cards to account-to-account payments. Prior to Vocalink he was Co-Head of Corporate Finance at Barclaycard. He also spent 10 years at NatWest where he held a number of senior roles including in their merchant acquiring and e-commerce business, Worldpay.

His appointment comes as the company broadens its offering of direct bank payment solutions for both one-off and recurring payments and builds out its suite of payment intelligence products to help businesses manage their payments more effectively. GoCardless will benefit from Stoddart’s expertise as it doubles down on account-to-account payments, with plans to release its Variable Recurring Payment feature shortly in the UK and expand Instant Bank Pay, its solution for one-off payments, across Europe.

Hiroki Takeuchi, co-founder and CEO at GoCardless, said: “This year marks an inflection point at GoCardless as we expand beyond recurring payments to serve a broader range of customer segments and payment use cases. Having the right people to lead us on this journey is critical as we scale our business, develop new products and services with open banking, and explore new markets. Paul has a unique depth of experience across both card and non-card payments and is well-positioned to help us seize the opportunities that will make GoCardless a force to be reckoned with in the payments space.”

Paul Stoddart, President at GoCardless, said: “GoCardless is in an incredibly exciting place right now. Hiroki and the team have already built a successful business by solving real customer problems. They have the foundations of a global bank pay network that will go from strength to strength as more businesses and people embrace account-to-account payments from bank debit to open banking-enabled payments. We will continue to push the boundaries of what’s possible in payments. In this new role at GoCardless I’ll have the opportunity to be part of the team building the new generation of payment solutions to do just that, with customer needs at the forefront.”

Stoddart’s appointment comes as GoCardless continues to accelerate its growth following its latest funding round of US$312 million in February. In the intervening months, GoCardless released its second open banking-enabled feature, Verified Mandates, in the UK and Success+, its ‘payment intelligence’ product which uses machine learning to identify the optimal day to recover failed payments, in the US.

In the UK, GoCardless recently signed its first Variable Recurring Payment customers and plans to introduce VRPs in both ‘sweeping’ and ‘non-sweeping’ forms over the coming months. By mid-2022, GoCardless will also integrate PayTo into its global bank payment platform in time for the regulated launch in Australia.

About GoCardless

GoCardless is a global leader in direct bank payment solutions, making it easy to collect both recurring and one-off payments directly from customers' bank accounts through direct debit and open banking. The GoCardless global payments network and technology platform take the pain out of getting paid for 70,000 businesses worldwide, from multinational corporations to small businesses. Each year GoCardless processes over US$30 billion of payments across more than 30 countries. GoCardless is headquartered in the UK, with additional offices in Australia, France, Germany and the United States. For more information, please visit www.gocardless.com and follow us on Twitter @GoCardless.

© 2022 GoCardless Ltd. All Rights Reserved. GoCardless is a registered trademark of GoCardless Ltd. in multiple countries. Third party trademarks mentioned above are owned by their respective companies. Unless explicitly identified as such, nothing in this press release should be construed to the contrary, or as an approval, endorsement or sponsorship by any third parties of GoCardless Ltd. or any aspect of this press release.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Linda Yang, Head of PR, GoCardless
lyang@gocardless.com
+44 7533575155

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Pelago Bioscience Acquires RG Discovery, Forming an Integrated Drug Discovery Partner Spanning Biology and Chemistry15.6.2026 10:00:00 EEST | Press release

Pelago Bioscience, a specialist drug discovery focused contract research organization (CRO), known for its industry-leading cell-based target engagement assays, is pleased to announce the acquisition of RG Discovery, and thereby adding deep expertise in medicinal chemistry, custom synthesis, and integrated drug discovery. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615340933/en/ Michael Dabrowski, Chief Executive Officer of Pelago Bioscience By combining Pelago Bioscience's biology-focused capabilities with RG Discovery's chemistry expertise, the enlarged platform will enable drug discovery teams to accelerate decision-making, streamline workflows, and advance programs more efficiently from hit identification through lead optimization. "Drug discovery increasingly requires seamless integration between chemistry and biology," said Michael Dabrowski, Chief Executive Officer of Pelago Bioscience. "By bringing RG Discovery

LTM Launches BlueVerse™ for iRun to Outcreate Managed Services in the Agentic AI Era15.6.2026 09:10:00 EEST | Press release

LTM, the Business Creativity partner to the world’s largest enterprises, today announced the launch of BlueVerse™ for iRun, an AI-native managed services model designed to transform traditional IT operations into a resilient, intelligent, and outcome-driven operating model. As enterprise environments grow more complex—spanning hybrid cloud, SaaS, and AI-driven ecosystems—traditional managed services models are increasingly constrained by siloed teams, static processes, and effort-led scaling. BlueVerse for iRun addresses this shift by moving beyond headcount-based delivery to a platform-led approach powered by agentic AI, knowledge convergence, and process-as-code. Built on the BlueVerse ecosystem, iRun creates a unified intelligence layer that brings together enterprise data, telemetry, workflows, and operational context—enabling AI to reason across systems, identify root causes, and execute actions within governed guardrails. iRun combines AI agents and human expertise to shift opera

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye